Inflammation Research

, Volume 61, Issue 11, pp 1241–1246 | Cite as

Serum vitronectin levels in patients with Behçet’s disease

  • Ali Yalçındağ
  • Aslıhan Uzun
  • F. Nilüfer Yalçındağ
  • Namık Delibaş
Original Research Paper
First Online:
Received:
Revised:
Accepted:
  • 170 Downloads

Abstract

Background/aims

To determine serum vitronectin levels in Behçet patients with and without ocular involvement, and to evaluate the relationship between vitronectin concentrations and clinical manifestations of Behçet’s disease (BD).

Methods

Sixty-five patients with BD and 21 control subjects were included. All patients were queried for the clinical manifestations of BD. Serum vitronectin concentrations were determined by using in vitro enzyme immunoassay kits.

Results

Serum vitronectin levels between the patients and the control subjects were not different. There was no statistically significant difference between vitronectin levels in Behçet patients with and without ocular involvement. No correlation was found between vitronectin concentrations and clinical manifestations.

Conclusion

This is the first study evaluating vitronectin levels in Behçet patients. Further studies involving larger numbers of subjects would be useful to improve our understanding of the functions of vitronectin in BD.

Keywords

Behçet’s disease Plasminogen activator inhibitor-1 Uveitis Vitronectin 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This study was supported by the Ankara University Research Fund (Project no: 10B3330022). The funding source had no involvement in study design, in the collection, analysis and interpretation of data, in the writing of the report and in the decision to submit the article for publication. We gratefully acknowledge the excellent technical assistance of Fatoş Özyalçın, Emine Özyurt and Meral Tiryaki.

Conflict of interest

None of the authors have any actual or potential conflict of interest, including any financial, personal or other relationships with any of the products or providers within 3 years of beginning the study.

References

  1. 1.
    Ekmekci H, Ekmekci OB, Sonmez H, Ozturk Z, Domanic N, Kokoglu E. Evaluation of fibronectin, vitronectin, and leptin levels in coronary artery disease: impacts on thrombosis and thrombolysis. Clin Appl Thromb Hemost. 2005;11:63–70.PubMedCrossRefGoogle Scholar
  2. 2.
    Ekmekci OB, Ekmekci H. Vitronectin in atherosclerotic disease. Clin Chim Acta. 2006;368:77–83.PubMedCrossRefGoogle Scholar
  3. 3.
    Reheman A, Gross P, Yang H, Chen P, Allen D, Leytin V, Freedman J, Ni H. Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation. J Thromb Haemost. 2005;3:875–83.PubMedCrossRefGoogle Scholar
  4. 4.
    Ekmekci H, Sonmez H, Ekmekci OB, Ozturk Z, Domanic N, Kokoglu E. Plasma vitronectin levels in patients with coronary atherosclerosis are increased and correlate with extent of disease. J Thromb Thrombolysis. 2002;14:221–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Fay WP, Parker AC, Ansari MN, Zheng X, Ginsburg D. Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood. 1999;93:1825–30.PubMedGoogle Scholar
  6. 6.
    Koschnick S, Konstantinides S, Schafer K, Crain K, Loskutoff DJ. Thrombotic phenotype of mice with a combined deficiency in plasminogen activator inhibitor 1 and vitronectin. J Thromb Haemost. 2005;3:2290–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Konstantinides S, Schafer K, Thinnes T, Loskutoff DJ. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation. 2001;103:576–83.PubMedCrossRefGoogle Scholar
  8. 8.
    Podor TJ, Peterson CB, Lawrence DA, Stefansson S, Shaughnessy SG, Foulon DM, Butcher M, Weitz JI. Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin. J Biol Chem. 2000;275:19788–94.PubMedCrossRefGoogle Scholar
  9. 9.
    Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol. 2003;10:541–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Preissner KT, Seiffert D. Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thromb Res. 1998;89:1–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Newall F, Johnston L, Ignjatovic V, Summerhayes R, Monagle P. Age-related reference ranges for two heparin-binding proteins: vitronectin and platelet factor 4. Int J Lab Hematol. 2009;31:683–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Mohri H, Ohkubo T. How vitronectin binds to activated glycoprotein IIb-IIIa complex and its function in platelet aggregation. Am J Clin Pathol. 1991;96:605–9.PubMedGoogle Scholar
  13. 13.
    Antonov AS, Antonova GN, Munn DH, Mivechi N, Lucas R, Catravas JD, Verin AD. αVβ3 integrin regulates macrophage inflammatory responses via PI3 kinase/Akt-dependent NF-κB activation. J Cell Physiol. 2011;226:469–76.PubMedCrossRefGoogle Scholar
  14. 14.
    Li R, Ren M, Chen N, Luo M, Zhang Z, Wu J. Vitronectin increases vascular permeability by promoting VE-cadherin internalization at cell junctions. PLoS One. 2012;7(5):e37195.PubMedCrossRefGoogle Scholar
  15. 15.
    International Study Group for Behcet’s disease. Criteria for diagnosis of Behcet’s disease. Lancet. 1990;335:1078–80.Google Scholar
  16. 16.
    Citirik M, Haznedaroglu IC, Teberik K, Soykan E, Zilelioglu O. Basic parameters of thrombophilia in ocular Behcet disease with posterior segment involvement. Br J Ophthalmol. 2009;93:1382–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Aguiar de Sousa D, Mestre T, Ferro JM. Cerebral venous thrombosis in Behcet’s disease: a systematic review. J Neurol. 2011;258:719–27.PubMedCrossRefGoogle Scholar
  18. 18.
    Yasar NS, Salgur F, Cansu DU, Kasifoglu T, Korkmaz C. Combined thrombophilic factors increase the risk of recurrent thrombotic events in Behcet’s disease. Clin Rheumatol. 2010;29:1367–72.PubMedCrossRefGoogle Scholar
  19. 19.
    Kiraz S, Ertenli I, Ozturk MA, Haznedaroglu IC, Celik I, Calguneri M. Pathological haemostasis and prothrombotic state in Behcet’s disease. Thromb Res. 2002;105:125–33.PubMedCrossRefGoogle Scholar
  20. 20.
    Krupa B, Cimaz R, Ozen S, Fischbach M, Cochat P, Kone-Paut I. Pediatric Behcet’s disease and thromboses. J Rheumatol. 2011;38:387–90.PubMedCrossRefGoogle Scholar
  21. 21.
    Probst K, Fijnheer R, Rothova A. Endothelial cell activation and hypercoagulability in ocular Behcet’s disease. Am J Ophthalmol. 2004;137:850–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Donmez A, Aksu K, Aydın H, Keser G, Cagirgan S, Doganavsargil E, Tombuloglu M. The plasma levels of activated thrombin activatable fibrinolysis inhibitor and thrombomodulin in Behcet disease and their association with thrombosis. Thromb Res. 2010;126:207–10.PubMedCrossRefGoogle Scholar
  23. 23.
    Donmez A, Aksu K, Celik HA, Keser G, Cagirgan S, Omay SB, Inal V, Aydın HH, Tombuloglu M, Doganavsargil E. Thrombin activatable fibrinolysis inhibitor in Behcet’s disease. Thromb Res. 2005;115:287–92.PubMedCrossRefGoogle Scholar
  24. 24.
    Citirik M, Berker N, Songur MS, Ozkan SS, Zilelioglu O. Ocular manifestations of late-onset Behcet disease. Ophthalmologica. 2011;225:21–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, Faezi T, Sadeghi Abdollahi B. How to deal with Behcet’s disease in daily practice. Int J Rheum Dis. 2010;13:105–16.PubMedCrossRefGoogle Scholar
  26. 26.
    Birengel S, Yalcindag FN, Yalcindag A, Sahli E, Batioglu F. Urokinase plasminogen activator receptor levels in Behcet’s disease. Thromb Res. 2011;128:274–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Espinosa G, Font J, Tassies D, Vidaller A, Deulofeu R, Lopez-Soto A, Cervera R, Ordinas A, Ingelmo M, Reverter JC. Vascular involvement in Behcet’s disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med. 2002;112:37–43.PubMedCrossRefGoogle Scholar
  28. 28.
    Akar S, Ozcan MA, Ates H, Gurler O, Alacacioglu I, Ozsan GH, Akkoc N, Ozkan S, Demirkan F, Onen F. Circulated activated platelets and increased platelet reactivity in patients with Behcet’s disease. Clin Appl Thromb Hemost. 2006;12:451–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Tomasson G, Monach PA, Merkel PA. Thromboembolic disease in vasculitis. Curr Opin Rheumatol. 2009;21:41–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Acikgoz N, Karincaoglu Y, Ermis N, Yagmur J, Atas H, Kurtoglu E, Cansel M, Barutcu I, Pekdemir H, Ozdemir R. Increased mean platelet volume in Behcet’s disease with thrombotic tendency. Tohoku J Exp Med. 2010;221:119–23.PubMedCrossRefGoogle Scholar
  31. 31.
    Mogulkoc N, Burgess MI, Bishop PW. Intracardiac thrombus in Behcet’s disease: a systematic review. Chest. 2000;118:479–87.PubMedCrossRefGoogle Scholar
  32. 32.
    Cekmen M, Evereklioglu C, Er H, Inaloz HS, Doganay S, Turkoz Y, Ozerol IH. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behcet’s syndrome. Int J Dermatol. 2003;42:870–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Ricart JM, Ramon LA, Vaya A, Espana F, Santaolaria ML, Todoli J, Castello R, Fontcuberta J, Estelles A. Fibrinolytic inhibitor levels and polymorphisms in Behcet disease and their association with thrombosis. Br J Haematol. 2008;141:716–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Yalcindag FN, Batioglu F, Ozdemir O, Cansizoglu E, Egin Y, Akar N. Soluble endothelial protein C receptor levels in Behçet patients with and without ocular involvement. Graefes Arch Clin Exp Ophthalmol. 2008;246:1603–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Behcet disease: evolution of clinical manifestations. Medicine (Baltimore). 2011;90:125–32.CrossRefGoogle Scholar
  36. 36.
    Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, Faezi T, Ghodsi Z, Faridar A, Ashofteh F, Sadeghi Abdollahi B. Behcet’s disease: from east to west. Clin Rheumatol. 2010;29:823–33.PubMedCrossRefGoogle Scholar
  37. 37.
    Atmaca L, Boyvat A, Yalcindag FN, Atmaca-Sonmez P, Gurler A. Behcet disease in children. Ocul Immunol Inflamm. 2011;19:103–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Guermazi S, Hamza M, Dellagi K. Protein S deficiency and antibodies to protein S in patients with Behcet’s disease. Thromb Res. 1997;86:197–204.PubMedCrossRefGoogle Scholar
  39. 39.
    Navarro S, Ricart JM, Medina P, Vaya A, Villa P, Todoli J, Estelles A, Mico ML, Aznar J, Espana F. Activated protein C levels in Behcet’s disease and risk of venous thrombosis. Br J Haematol. 2004;126:550–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Chafa O, Fischer AM, Meriane F, Chellali T, Sternberg C, Otmani F, Benebadji M. Behcet syndrome associated with protein S deficiency. Thromb Haemost. 1992;67:1–3.PubMedGoogle Scholar
  41. 41.
    Lenk N, Ozet G, Alli N, Coban O, Erbasi S. Protein C and protein S activities in Behcet’s disease as risk factors of thrombosis. Int J Dermatol. 1998;37:124–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Nalcaci M, Pekcelen Y. Antithrombin III, protein C and protein S plasma levels in patients with Behcet’s disease. J Int Med Res. 1998;26:206–8.PubMedGoogle Scholar
  43. 43.
    Ozturk MA, Ertenli I, Kiraz S, Haznedaroglu IC, Celik I, Kirazli S, Calguneri M. Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behcet’s disease. Rheumatol Int. 2004;24:98–102.PubMedCrossRefGoogle Scholar
  44. 44.
    Derer W, Barnathan ES, Safak E, Agarwal P, Heidecke H, Möckel M, Gross M, Ozcelik C, Dietz R, Dechend R. Vitronectin concentrations predict risk in patients undergoing coronary stenting. Circ Cardiovasc Interv. 2009;2:14–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Gawaz M, Neumann FJ, Dickfeld T, Reininger A, Adelsberger H, Gebhardt A, Schomig A. Vitronectin receptor (alpha(v)beta3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction. Circulation. 1997;96:1809–18.PubMedCrossRefGoogle Scholar
  46. 46.
    Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, Bussolino F. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J. 1999;18:882–92.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel AG 2012

Authors and Affiliations

  • Ali Yalçındağ
    • 1
  • Aslıhan Uzun
    • 2
  • F. Nilüfer Yalçındağ
    • 2
  • Namık Delibaş
    • 1
  1. 1.Department of Clinical BiochemistryDışkapı Yıldırım Beyazıt Training and Research HospitalAnkaraTurkey
  2. 2.Department of OphthalmologyAnkara University Faculty of MedicineAnkaraTurkey

Personalised recommendations